Autres langues Karyopharm Therapeutics Inc.

Actions

KPTI

US48576U2050

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,8022 ^USD	-7,45%		-50,48%	-89,10%

31/08	Karyopharm Therapeutics dépose auprès de la FDA une demande complémentaire d’autorisation de mise sur le marché pour Xpovio (selinexor) associé au ruxolitinib chez les patients atteints de myélofibrose	CI
29/08	Transcript : Karyopharm Therapeutics Inc. - Special Call

Autres langues

01/10	Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/09	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/08	Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis
31/08	Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
13/08	Karyopharm Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026
13/08	Karyopharm Therapeutics: Q2 Earnings Snapshot
13/08	Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
10/08	Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
03/08	Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
31/07	Top Midday Decliners
30/07	Karyopharm Therapeutics Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
30/07	Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
30/07	Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
30/07	Karyopharm Therapeutics Inc. Plans To Submit Supplemental New Drug Application For Selinexor Plus Ruxolitinib In Myelofibrosis Under Accelerated Approval Pathway
01/07	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 2500 Growth Benchmark
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 2000 Index
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 2000 Value Benchmark
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 2000 Growth Benchmark
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 3000E Index
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 3000E Growth Benchmark
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 2000 Dynamic Index
29/06	Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 3000 Value Benchmark